Adjuvant PD-1 blockade for mismatch repair-deficient solid cancers directed by ctDNA status delivers clinical benefit

Published Date: 30 Apr 2025

Pembrolizumab (Keytruda), an anti-PD-1 antibody, cleared minimal residual disease and protected against recurrence in patients with DNA mismatch repair-deficient (dMMR) early-stage solid cancers who had detectable circulating ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.

2.

Researchers use AI to monitor side effects of chemotherapy and support families dealing with pediatric cancer.

3.

Study finds 20 minutes of mindful breathing can rapidly reduce intensity of cancer pain

4.

Report suggests a big improvement in lung cancer survival

5.

The clinical trial of ENZAMET shows promise as a treatment for prostate cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot